Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group.

@article{Rapoport1997OptimizingTD,
  title={Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group.},
  author={Alan Mark Rapoport and Nabih M. Ramadan and James U. Adelman and Ninan T. Mathew and Arthur H. Elkind and David B. Kudrow and Nancy L. Earl},
  journal={Neurology},
  year={1997},
  volume={49 5},
  pages={
          1210-8
        }
}
This study investigated the efficacy of zolmitriptan (Zomig, formerly 311C90) in acute migraine therapy. Patients with a history of migraine were randomized in a double-blind, multicenter, placebo-controlled, dose range-finding study of oral zolmitriptan 1, 2.5, 5, or 10 mg versus placebo for the treatment of a severe or moderate migraine headache. Patients with persistent or recurrent headache 4 to 24 hours after the initial dose, who did not take escape medication, were eligible to receive a… CONTINUE READING
BETA

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 27 CITATIONS

Similar Papers

Loading similar papers…